SCHEMBL4071306

SCHEMBL4071306

CC(C)(C)c1cc(C=C(C#N)S(=O)(=O)c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc(C(C)(C)C)c1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
HSD17B10 Q99714 4/20 0.59
HPGD P15428 4/20 0.59
CYP3A4 P08684 3/20 0.59
MAPT P10636 3/20 0.59
TSHR P16473 3/20 0.59
BLM P54132 3/20 0.59
ALDH1A1 P00352 3/20 0.59
ALOX15 P16050 3/20 0.59
CYP1A2 P05177 3/20 0.59
CYP2C9 P11712 3/20 0.59
RGS12 O14924 2/20 0.59
GMNN O75496 2/20 0.59
LMNA P02545 2/20 0.59
TP53 P04637 2/20 0.59
NFKB1 P19838 2/20 0.59
CYP2C19 P33261 2/20 0.59
THPO P40225 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071302 1.00 MEN1 (0.59) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL3240249 0.89 ALDH1A1 (0.61) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL3240240 0.89 ALDH1A1 (0.61) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL3240244 0.89 ALDH1A1 (0.61) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL4070166 0.88 HPGD (0.52) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL4070167 0.88 HPGD (0.52) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL4070529 0.88 HPGD (0.57) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL4071011 0.88 HPGD (0.52) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL4070530 0.88 HPGD (0.57) MEN1KMT2ASMN1; SMN2HSD17B10HPGD
SCHEMBL4071014 0.88 HPGD (0.52) MEN1KMT2ASMN1; SMN2HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP claimed
JP-2007503453-A 2007-02-22 JP claimed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US claimed
EP-1625112-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-02-15 EP claimed
WO-2004101505-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-11-25 WO claimed
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP disclosed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US disclosed
EP-1625112-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-02-15 EP disclosed
WO-2004101505-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128662-A1 Novel compounds for treatment of obesity GPR119, FABP4, HSD17B4 MEN1 4794/4885KMT2A 2506/4885SMN1; SMN2 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.